TY - JOUR
T1 - Effectiveness of antiplatelet therapy for Kawasaki disease
T2 - a systematic review
AU - Tanoshima, Reo
AU - Hashimoto, Risa
AU - Suzuki, Takanori
AU - Ishiguro, Akira
AU - Kobayashi, Tohru
N1 - Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2019
Y1 - 2019
N2 - Kawasaki disease is an acute systemic vasculitis in children. Antiplatelet medicines are commonly used for Kawasaki disease to attenuate vasculitis and prevent thromboembolism; however, the mechanisms have not been elucidated. The objective of this study is to assess the effectiveness of antiplatelet medications for Kawasaki disease. We used Medline, Embase, Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi (Ichushi) from January 1947 to August 2018. Studies describing the platelet functions of antiplatelet drugs for Kawasaki disease were included. Twenty studies met the inclusion criteria. There were no randomized controlled trials. Seven studies compared platelet aggregation ability before and after treatment. Eight studies compared platelet aggregation with that in Kawasaki disease patients without treatment. Four studies compared aggregation among different types of antiplatelet drugs or at different doses. Antiplatelet medications administered in the studies included aspirin, flurbiprofen, dipyridamole, and choline salicylate. Methods for the measurement of platelet aggregation ability varied among studies. The groups with antiplatelet treatment tended to have a decreased platelet aggregation function. The statistical analyses were impossible due to insufficient quantitative data and heterogeneity among the studies. Conclusion: The present systematic review revealed that there was insufficient evidence for the effectiveness of antiplatelet therapy for Kawasaki disease.What is Known:• Antiplatelet therapy is widely used for Kawasaki disease to mitigate cardiac complications.• The mechanisms of antiplatelet therapy for Kawasaki disease are not clarified.What is New:• This systematic review showed that the groups with antiplatelet treatment tended to have a decreased platelet aggregation function.• There is insufficient evidence for the effectiveness of antiplatelet therapy for Kawasaki disease.
AB - Kawasaki disease is an acute systemic vasculitis in children. Antiplatelet medicines are commonly used for Kawasaki disease to attenuate vasculitis and prevent thromboembolism; however, the mechanisms have not been elucidated. The objective of this study is to assess the effectiveness of antiplatelet medications for Kawasaki disease. We used Medline, Embase, Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi (Ichushi) from January 1947 to August 2018. Studies describing the platelet functions of antiplatelet drugs for Kawasaki disease were included. Twenty studies met the inclusion criteria. There were no randomized controlled trials. Seven studies compared platelet aggregation ability before and after treatment. Eight studies compared platelet aggregation with that in Kawasaki disease patients without treatment. Four studies compared aggregation among different types of antiplatelet drugs or at different doses. Antiplatelet medications administered in the studies included aspirin, flurbiprofen, dipyridamole, and choline salicylate. Methods for the measurement of platelet aggregation ability varied among studies. The groups with antiplatelet treatment tended to have a decreased platelet aggregation function. The statistical analyses were impossible due to insufficient quantitative data and heterogeneity among the studies. Conclusion: The present systematic review revealed that there was insufficient evidence for the effectiveness of antiplatelet therapy for Kawasaki disease.What is Known:• Antiplatelet therapy is widely used for Kawasaki disease to mitigate cardiac complications.• The mechanisms of antiplatelet therapy for Kawasaki disease are not clarified.What is New:• This systematic review showed that the groups with antiplatelet treatment tended to have a decreased platelet aggregation function.• There is insufficient evidence for the effectiveness of antiplatelet therapy for Kawasaki disease.
UR - http://www.scopus.com/inward/record.url?scp=85064174011&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064174011&partnerID=8YFLogxK
U2 - 10.1007/s00431-019-03368-x
DO - 10.1007/s00431-019-03368-x
M3 - Article
C2 - 30923908
AN - SCOPUS:85064174011
JO - Acta Paediatrica Hungarica
JF - Acta Paediatrica Hungarica
SN - 0340-6199
ER -